findmyKOL

Martin Edelman, MD

Enriched profile

Chair, Department of Hematology/Oncology, Fox Chase Cancer Center; Professor, Department of Hematology/Oncology; G. Morris Dorrance Jr. Chair in Medical Oncology; Chair, Department of Medical Oncology, Lewis Katz School of Medicine at Temple University · Fox Chase Cancer Center

ORCIDNPI
Region🇺🇸 Philadelphia, PA · Northeast · United StatesSpecialtyMedical OncologyFocusLung Cancer Treatments and Mutations+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Martin Edelman is Chair, Department of Hematology/Oncology, Fox Chase Cancer Center; Professor, Department of Hematology/Oncology; G. Morris Dorrance Jr. Chair in Medical Oncology; Chair, Department of Medical Oncology, Lewis Katz School of Medicine at Temple University at Fox Chase Cancer Center. OpenAlex indexes 505 publications with 14,152 citations (h-index 60); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 1 Sept 2026

Martin Edelman, MD, is Chair, Department of Hematology/Oncology, Fox Chase Cancer Center. The public record shows 505 publications with 14,152 citations (h-index 60), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 27 companies.

  • Most recent indexed publication: 2026 · JCO precision oncology
  • Top research focus: Lung Cancer Treatments and Mutations
  • 15 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 27 companies

Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)11 trialsSmall Cell Lung Carcinoma5 trialsBladder / Urothelial Cancer1 trialUrethral Neoplasms1 trialHead & Neck Cancer1 trialCarcinoma, Squamous Cell1 trialCarcinoma, Small Cell1 trialBreast Cancer1 trialProstate Cancer1 trial

Research focus

OpenAlex concept fingerprint
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research StudiesCancer Immunotherapy and BiomarkersCancer Treatment and Pharmacology

Drugs & molecules

across trials, industry payments and publications
CarboplatinClinical trials1Industry paymentsPublications3PaclitaxelClinical trials1Industry paymentsPublications2CisplatinClinical trials1Industry paymentsPublications1

Works with

trial sponsors and companies reporting payments
Jazz Pharmaceuticals Inc.Clinical trialsIndustry payments15GlaxoSmithKline, LLC.Clinical trialsIndustry payments10AstraZeneca Pharmaceuticals LPClinical trialsIndustry payments9

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
505publications

Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.

14,152citations

Total citations across indexed works.

60h-index

Hirsch index (OpenAlex). i10-index 199.

Clinical & industry

trials, payments and federal funding
15clinical trials

Investigator role on registered studies.

View trials
27companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 1 Sept 2026

Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 1 Sept 2026

27 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    55.1%
    Kinase inhibitor35.5%
    Tagrisso100%
    Part D<11 patients
    Nonsteroidal Anti-inflammatory Drug11.6%
    Celecoxib100%
    Part D<11 patients
  • Nervous system

    14.5%
    Opioid Agonist14.5%
    Oxycodone Hcl100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    11.6%
    Potassium supplement11.6%
    Potassium Chloride100%
    Part D<11 patients
2 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)92.5% facility · 7.5% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 1 Sept 2026

115 congress contributions (2004–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:

Publications

Updated 1 Sept 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 1 Sept 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 1 Sept 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/martin-edelman-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/martin-edelman-0aa29a28

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • Other

    profiles.foxchase.org/en/persons/martin-edelman

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.foxchase.org
1 more verified account behind the reveal.Reveal →

Mentions by others

where others cite or feature them
  • Other

    iaslc.org/iaslc-news/lung-cancer-considered/interview-iaslc-president-dr-tetsuya-mitsudomi

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org
  • LinkedIn

    linkedin.com/posts/fox-chase-cancer-center_dr-martin-edelman-appointed-inaugural-chair-activity-7087852423452446721-6YHo

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
1 more mention behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 1 Sept 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Fellowship in Hematology/Oncology

    Naval Hospital, San Diego

    1990
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org
  • Residency in Internal Medicine

    Naval Hospital, San Diego

    1986
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org
  • MD

    Albany Medical College

    1982
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org
  • BS in Biology (cum laude)

    Rensselaer Polytechnic Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org
  • Board Certified

    American Board of Internal Medicine (Internal Medicine and Medical Oncology)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org

Editorial & leadership roles

journal and society appointments
  • Member

    Executive Committee, American Radium Society

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.foxchase.org
  • Chair

    Scientific Advisory Board, Lung Cancer Foundation of America

    2018
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lcfamerica.org
  • Member

    Small Cell Lung Cancer Panel, NCCN

    2017
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.foxchase.org
5 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record
4 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Chair

    Department of Medical Oncology, Lewis Katz School of Medicine at Temple University

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foxchase.org
  • Formerly Physician and Director

    Solid Tumor Oncology, University of Maryland Marlene and Stewart Greenebaum Cancer Center

    2017
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lcfamerica.org
  • Associate Cancer Center Director for Clinical Research Integration

    Fox Chase Cancer Center / Temple University Health System

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.foxchase.org

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.